MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Clinical Trials / Integra Lifesciences touts Cadence ankle study

Integra Lifesciences touts Cadence ankle study

September 20, 2019 By Sean Whooley Leave a Comment

Integra LifeSciencesIntegra LifeSciences (NSDQ:IART) yesterday touted positive findings from its Cadence total ankle system retrospective study and closed enrollment ahead of schedule for two post-market studies of the device.

The study reported that patients treated with Cadence while suffering from end-stage arthritis experienced improvements in quality of life, functional measures and pain. The results were presented during the American Orthopaedic Foot & Ankle Society meeting in Chicago last week.

In the U.S., 131 patients were enrolled at 12 study centers between August 2017 and February 2019. The company expects two-year follow-up data to be published in 2021.

“The physicians involved in the Cadence total ankle system post-market studies are excited that the implant has been performing very well,” lead investigator Dr. Tim Daniels of the University of Toronto said in prepared remarks. “The undertaking of these studies signifies Integra LifeSciences’ commitment to scientific rigor and ensuring patient outcomes are being properly assessed and followed.”

The Cadence system is designed to accommodate various patient anatomies, reduce potential clinical complications and address common challenges associated with ankle arthroplasty procedures.

Integra Lifesciences also hit its target enrollment for Cadence system post-market studies in the U.S. and Europe, both ahead of schedule. The company said they are the first multi-center prospective studies conducted on the Cadence system, which was launched in 2016.

Shares of IART were down -0.1% at $60.94 per share in late-afternoon trading today.

Filed Under: Clinical Trials, Orthopedics, Surgical Tagged With: Extremities, Integra LifeSciences

In case you missed it

  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot
  • Natus Medical issues field safety notice for snap electrode leads
  • J&J’s Ethicon gets to substitute 20 new claims on surgical stapler patent
  • Minerva Surgical raises $10m
  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • Orthofix names new president of global spine business
  • J&J Vision launches Tecnis Toric II intraocular lens in U.S.
  • NOUS Imaging picks up $6.6m for brain-imaging software
  • MicroVention issues safety notice for Azur endovascular embolization products
  • New study touts positive long-term results for Boston Sci’s Watchman
  • 3M issues safety notice for Durapore Advanced surgical tape
  • FDA clearance positions Sight Diagnostics to deliver on two-drop blood testing promise

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS